«Previous Article|Table of Contents|Next Article»

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:

2023 09

Page:

1660-1665

Research Field:

Publishing date:

Info

Title:

Retrospective analysis of the discordance in ER,PR,HER-2 and Ki-67 expression between recurrent metastasis and primary sites in breast cancer patients

Author(s):

HE Xin¹; PENG Shujia²; SHI Hong¹

1.Department of Oncology;2.Department of General Surgery£¬the Second Affiliated Hospital of Air Force Medical University,Shaanxi Xi'an 710038,China.

Keywords:

breast cancer; biomarker discordance; disease-free survival

PACS:

R737.9

DOI:

10.3969/j.issn.1672-4992.2023.09.014

Abstract:

Objective:To investigate the differential expressions of ER,PR,HER-2 and Ki-67 in primary and recurrent metastasis breast cancer patients.Further,analyze their effects on disease-free survival of breast cancer patients.Methods:The medical records from January 01,2012 to December 31,2021 were collected by case retrieval system of our hospital.Excluding cases with missing pathological and clinical data,a total of 89 cases with recurrent metastasis breast cancer were included in this study.The clinical characteristics£¬including ER,PR,HER-2 and Ki-67 status of patients were recorded in detail,and the discordance between recurrent metastasis and primary sites were further studied by survival analysis.Results:The mean age of the enrolled patients was 53.14 years (20~84 years).All patients underwent radical mastectomy or modified radical mastectomy,and corresponding postoperative adjuvant therapy.Among them,34 patients received preoperative neoadjuvant therapy.The positive expression rates of ER and PR in the primary breast cancer were higher than those in metastasis sites.High expression of HER-2 and Ki-67 were more common in recurrent metastasis sites.The differences of ER£¬PR,HER-2 and Ki-67 expression in primary lesions and recurrent metastasis lesions were 24.72%£¬42.70%£¬11.24%and 13.48%£¬respectively.Biomarker discordance of ER and PR expression were correlated with disease-free survival.Conclusion:The inconsistent expression of ER,PR,HER-2 and Ki-67 in breast cancer patients between primary and recurrent metastasis lesions,may further affects the treatment strategy and survival of patients.

References:

£Û1£ÝBRAY F,FERLAY J,SOERJOMATARAM I,et al.Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries £ÛJ£Ý.CA Cancer J Clin,2018,68(6):394-424.
£Û2£ÝMASUDA N,LEE SJ,OHTANI S,et al.Adjuvant capecitabine for breast cancer after preoperative chemotherapy £ÛJ£Ý.N Engl J Med,2017,376(22):2147-2159.
£Û3£ÝAMIR E,CLEMONS M,PURDIE CA,et al.Tissue confirmation of disease recurrence in breast cancer patients:pooled analysis of multi-centre,multi-disciplinary prospective studies £ÛJ£Ý.Cancer Treat Rev,2012,38(6):708-714.
£Û4£ÝJABBOUR MN,MASSAD CY,BOULOS FI.Variability in hormone and growth factor receptor expression in primary versus recurrent,metastatic,and post-neoadjuvant breast carcinoma £ÛJ£Ý.Breast Cancer Res Treat,2012,135(1):29-37.
£Û5£ÝROSSI S,BASSO M,STRIPPOLI A,et al.Hormone receptor status and HER2 expression in primary breast cancer compared with synchronous axillary metastases or recurrent metastatic disease £ÛJ£Ý.Clin Breast Cancer,2015,15(5):307-312.
£Û6£ÝNIIKURA N,LIU J,HAYASHI N,et al.Loss of human epidermal growth factor receptor 2 (HER2) expression in metastatic sites of HER2-overexpressing primary breast tumors£ÛJ£Ý.J Clin Oncol,2012,30(6):593-599.
£Û7£ÝALKNER S,EHINGER A,BENDAHL PO,et al.Prognosis,stage and oestrogen receptor status of contralateral breast cancer in relation to characteristics of the first tumour,prior endocrine treatment and radiotherapy £ÛJ£Ý.Eur J Cancer,2015,51(16):2304-2313.
£Û8£ÝGIULIANO AE,EDGE SB,HORTOBAGYI GN.Eighth edition of the AJCC cancer staging manual:Breast cancer £ÛJ£Ý.Ann Surg Oncol,2018,25(7):1783-1785.
£Û9£ÝSENKUS E,KYRIAKIDES S,OHNO S,et al.Primary breast cancer:ESMO Clinical Practice Guidelines for diagnosis,treatment and follow-up £ÛJ£Ý.Ann Oncol,2015,26£¨Suppl 5£©:8-30.
£Û10£ÝHAMMOND ME,HAYES DF,WOLFF AC,et al.American society of clinical oncology/college of American pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer £ÛJ£Ý.J Oncol Pract,2010£¬6(4):195-197.
£Û11£ÝVANG NIELSEN K,JORGENSEN JT,SCHONAU A,et al.Human epidermal growth factor receptor 2 testing in breast cancer £ÛJ£Ý.J Clin Oncol,2007,25(25):4020.
£Û12£ÝYERUSHALMI R,WOODS R,RAVDIN PM,et al.Ki67 in breast cancer:prognostic and predictive potential £ÛJ£Ý.Lancet Oncol,2010,11(2):174-183.
£Û13£ÝCALDARELLA A,CROCETTI E,PACI E.Ki67 in breast cancer:a useful prognostic marker£ÛJ£Ý.Ann Oncol,2014,25(2):542.
£Û14£ÝCLARK BZ,ONISKO A,ASSYLBEKOVA B,et al.Breast cancer global tumor biomarkers:a quality assurance study of intratumoral heterogeneity £ÛJ£Ý.Mod Pathol£¬2019£¬32(3):354-366.
£Û15£ÝLI S,WU J,HUANG O,et al.Association of molecular biomarker heterogeneity with treatment pattern and disease outcomes in multifocal or multicentric breast cancer£ÛJ£Ý.Front Oncol£¬2022£¬12:833093.
£Û16£ÝALZUBI MA,TURNER TH,OLEX AL,et al.Separation of breast cancer and organ microenvironment transcriptomes in metastases £ÛJ£Ý.Breast Cancer Res,2019,21(1):36.
£Û17£ÝXIE QM,HU HQ,LI SS,et al.Association of oestrogen receptor alpha gene polymorphisms with systemic lupus erythematosus risk:An updated meta-analysis £ÛJ£Ý.Microb Pathog,2019,127:352-358.
£Û18£ÝMEDEIROS B,ALLAN AL.Molecular mechanisms of breast cancer metastasis to the lung:clinical and experimental perspectives £ÛJ£Ý.Int J Mol Sci,2019,20(9)£º2272.
£Û19£ÝAURILIO G,DISALVATORE D,PRUNERI G,et al.A meta-analysis of oestrogen receptor,progesterone receptor and human epidermal growth factor receptor 2 discordance between primary breast cancer and metastases £ÛJ£Ý.Eur J Cancer,2014,50(2):277-289.
£Û20£ÝCHANG HJ,HAN SW,OH DY,et al.Discordant human epidermal growth factor receptor 2 and hormone receptor status in primary and metastatic breast cancer and response to trastuzumab £ÛJ£Ý.Jpn J Clin Oncol,2011,41(5):593-599.
£Û21£ÝNOGAMI T,SHIEN T,TANAKA T,et al.The discordance between primary breast cancer lesions and pulmonary metastatic lesions in expression of aldehyde dehydrogenase 1-positive cancer cells £ÛJ£Ý.Breast Cancer,2014£¬21(6):698-702.
£Û22£ÝSHIINO S,KINOSHITA T,YOSHIDA M,et al.Prognostic impact of discordance in hormone receptor status between primary and recurrent sites in patients with recurrent breast cancer £ÛJ£Ý.Clin Breast Cancer,2016,16(4):133-140.
£Û23£ÝSINGH K,TANTRAVAHI U,LOMME MM,et al.Updated 2013 College of American Pathologists/American Society of Clinical Oncology (CAP/ASCO) guideline recommendations for human epidermal growth factor receptor 2 (HER2) fluorescent in situ hybridization (FISH) testing increase HER2 positive and HER2 equivocal breast cancer cases;retrospective study of HER2 FISH results of 836 invasive breast cancers £ÛJ£Ý.Breast Cancer Res Treat,2016,157(3):405-411.
£Û24£ÝWOLFF AC,HAMMOND ME,HICKS DG,et al.Recommendations for human epidermal growth factor receptor 2 testing in breast cancer:American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update £ÛJ£Ý.J Clin Oncol,2013,31(31):3997-4013.
£Û25£ÝLIM TH,LIM AS,THIKE AA,et al.Implications of the updated 2013 American society of clinical oncology/college of American pathologists guideline recommendations on human epidermal growth factor receptor 2 gene testing using immunohistochemistry and fluorescence in situ hybridization for breast cancer £ÛJ£Ý.Arch Pathol Lab Med,2016,140(2):140-147.
£Û26£ÝTIMMER M,WERNER JM,ROHN G,et al.Discordance and conversion rates of progesterone-,estrogen-,and HER2/neu-receptor status in primary breast cancer and brain metastasis mainly triggered by hormone therapy £ÛJ£Ý.Anticancer Res,2017,37(9):4859-4865.
£Û27£ÝNISHIMURA R,OSAKO T,OKUMURA Y,et al.Changes in the ER,PgR,HER2,p53 and Ki-67 biological markers between primary and recurrent breast cancer:discordance rates and prognosis £ÛJ£Ý.World J Surg Oncol,2011,9:131.
£Û28£ÝIBRAHIM T,FAROLFI A,SCARPI E,et al.Hormonal receptor,human epidermal growth factor receptor-2,and Ki67 discordance between primary breast cancer and paired metastases:clinical impact £ÛJ£Ý.Oncology,2013,84(3):150-157.
£Û29£Ý CRISCITIELLO C£¬ANDR¦I F£¬THOMPSON AM£¬et al.Biopsy confirmation of metastatic sites in breast cancer patients:clinical impact and future perspectives £ÛJ£Ý.Breast Cancer Res£¬2014£¬16£¨2£©:205-213.
£Û30£Ý PENG L,ZHANG Z,ZHAO D,et al.Discordance in ER,PR,HER2,and Ki-67 expression between primary and recurrent/metastatic lesions in patients with primary early stage breast cancer and the clinical significance:retrospective analysis of 75 cases £ÛJ£Ý.Pathol Oncol Res,2021,27:599894.
£Û31£Ý¹ùæã¬ÁõÒ¢°î£¬ÁõÐÂÀ¼.ÈéÏÙ°©Ô­·¢ÔתÒÆÔîER¡¢PR¼°HER2±í´ï¶ÔÔ¤ºóµÄÓ°Ïì£ÛJ£Ý.ÄþÏÄÒ½¿Æ´óѧѧ±¨£¬2021£¬43£¨9£©£º887-893. GUO T,LIU RB,LIU XL.The impact of the expression of ER£¬PR and HER2 in primary breast cancer and metastasis on the prognosis £ÛJ£Ý.Journal of Ningxia Medical University£¬2021£¬43£¨9£©£º887-893.
£Û32£Ý ZARDAVAS D,IRRTHUM A,SWANTON C,et al.Clinical management of breast cancer heterogeneity£ÛJ£Ý.Nat Rev Clin Oncol,2015,12(7):381-394.

Memo

Memo:

National Natural Science Foundation of China(No.81302284£©£»¹ú¼Ò×ÔÈ»¿Æѧ»ù½ð£¨±àºÅ£º81302284£©

Common functions

Last Update: 2023-03-30